Potassium citrate

Description

Potassium citrate extended-release tablets are a citrate salt of potassium, with an empirical formula of K₃C₆H₅O₇ • H₂O. These tablets are presented as off-white to tan yellowish, oral wax-matrix formulations. Each tablet contains 5 mEq (540 mg), 10 mEq (1080 mg), or 15 mEq (1620 mg) of potassium citrate. Inactive ingredients include carnauba wax, silicon dioxide, and magnesium stearate. The FDA-approved dissolution test specifications for this formulation differ from those established by the USP.

Uses and Indications

Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) associated with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis, with or without calcium stones.

There are no teratogenic or nonteratogenic effects associated with the use of this medication.

Dosage and Administration

For patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq per day. This can be administered as 30 mEq two times per day or 20 mEq three times per day. Doses should be taken with meals, within 30 minutes after meals, or at bedtime as a snack.

In cases of mild to moderate hypocitraturia (urinary citrate > 150 mg/day), therapy should commence at a dosage of 30 mEq per day. This may be given as 15 mEq two times per day or 10 mEq three times per day, also to be taken with meals, within 30 minutes after meals, or at bedtime as a snack.

It is essential to adhere to these dosing schedules to optimize therapeutic outcomes and ensure patient safety.

Contraindications

Use of this product is contraindicated in the following situations:

Patients with hyperkalemia or conditions predisposing to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown, due to the risk of exacerbating elevated potassium levels.

Patients with gastrointestinal conditions that may cause arrest or delay in tablet passage, such as delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture, as these conditions may hinder proper absorption and efficacy.

Patients with peptic ulcer disease, as the product may exacerbate gastrointestinal irritation.

Patients with active urinary tract infections, due to the potential for worsening the infection or complicating treatment.

Patients with renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 ml/kg/min, as this may lead to accumulation of the product and increased risk of adverse effects.

Warnings and Precautions

Patients receiving potassium citrate must be closely monitored for the development of hyperkalemia, particularly in those with compromised renal function or conditions that impair potassium excretion, such as severe myocardial damage or heart failure. The administration of potassium citrate in these populations poses a significant risk of hyperkalemia, which can lead to cardiac arrest. It is crucial to recognize that hyperkalemia may develop rapidly and can be asymptomatic, necessitating vigilant monitoring of potassium levels in at-risk patients (5.1).

In the event of severe vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate should be discontinued immediately. These symptoms may indicate serious underlying conditions such as bowel perforation or obstruction, which require prompt medical evaluation (5.2).

Healthcare professionals are advised to remain alert to these potential complications and to ensure appropriate laboratory tests are conducted to monitor potassium levels and assess gastrointestinal health as needed.

Side Effects

Patients may experience a range of adverse reactions associated with potassium citrate administration. Common adverse reactions include minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, loose bowel movements, and nausea.

Serious adverse reactions can occur, particularly in patients with impaired mechanisms for excreting potassium. Hyperkalemia is a significant concern, as it can lead to cardiac arrest. This condition may develop rapidly and can be asymptomatic, making it potentially fatal. Therefore, the use of potassium citrate is contraindicated in patients with chronic renal failure or any other conditions that impair potassium excretion, such as severe myocardial damage or heart failure.

In addition to hyperkalemia, gastrointestinal lesions may arise. If patients experience severe vomiting, abdominal pain, or gastrointestinal bleeding, potassium citrate should be discontinued immediately, and an investigation for bowel perforation or obstruction should be conducted.

Additional considerations include patients with pre-existing hyperkalemia or conditions that predispose them to hyperkalemia, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, or extensive tissue breakdown. Furthermore, caution is advised in patients who may experience delays in tablet passage through the gastrointestinal tract, including those with delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture. Patients with peptic ulcer disease, active urinary tract infections, or renal insufficiency (with a glomerular filtration rate of less than 0.7 ml/kg/min) should also be closely monitored.

Drug Interactions

Concomitant administration of potassium-sparing diuretics is contraindicated due to the potential for severe hyperkalemia. It is advised to avoid the use of these agents together.

Drugs that slow gastrointestinal transit time, including anticholinergics, may exacerbate gastrointestinal irritation associated with potassium salts. Caution is recommended when these agents are used concurrently.

For patients receiving renin-angiotensin-aldosterone inhibitors, monitoring for hyperkalemia is essential. Regular assessment of potassium levels is advised to prevent complications.

Nonsteroidal anti-inflammatory drugs (NSAIDs) may also increase the risk of hyperkalemia. It is important to monitor potassium levels in patients taking NSAIDs alongside other medications that can elevate potassium.

Packaging & NDC

The table below lists all NDC Code configurations of Potassium Citrate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Therefore, the use of this medication in children is not recommended until further data is available to support its use in this population.

Geriatric Use

Elderly patients may exhibit impaired mechanisms for excreting potassium, which can increase the risk of hyperkalemia and potentially lead to cardiac arrest. Therefore, it is essential for healthcare providers to closely monitor these patients for signs of hyperkalemia, particularly in those with chronic renal failure or other conditions that may compromise potassium excretion.

While there are no specific dosage adjustments recommended for elderly patients, the absence of such adjustments does not negate the need for careful consideration of individual patient factors. Given the heightened risk of adverse effects in this population, vigilant monitoring and assessment are crucial to ensure patient safety.

Pregnancy

Pregnant patients should be aware that animal reproduction studies have not been conducted with potassium citrate. Therefore, it is not known whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Given the lack of data, potassium citrate should be prescribed to pregnant women only if clearly needed, weighing the potential benefits against any unknown risks. Healthcare professionals are advised to exercise caution and consider alternative treatments when appropriate.

Lactation

Potassium citrate is not known to affect the normal potassium ion content of human milk, which is approximately 13 mEq/L. Due to the lack of data on its excretion in breast milk and potential effects on breastfed infants, potassium citrate should be administered to lactating mothers only if clearly needed.

Renal Impairment

Patients with renal impairment may experience significant risks associated with potassium citrate administration. In individuals with compromised mechanisms for potassium excretion, the use of potassium citrate can lead to hyperkalemia, which may progress rapidly and can be asymptomatic, potentially resulting in cardiac arrest. Therefore, potassium citrate should be avoided in patients with chronic renal failure or any other conditions that impair potassium excretion, such as severe myocardial damage or heart failure. Monitoring of potassium levels is essential in these populations to prevent serious adverse effects.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there is no information available regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population.

Overdosage

In cases of overdosage, particularly with potassium salts, it is essential to recognize that while serious hyperkalemia is rare at recommended dosages in individuals without predisposing conditions, the potential for hyperkalemia exists. This condition is often asymptomatic, typically indicated only by elevated serum potassium levels and specific electrocardiographic changes, including T-wave peaking, loss of the P-wave, S-T segment depression, and QT interval prolongation. Late-stage manifestations may include muscle paralysis and cardiovascular collapse due to cardiac arrest.

Management of Hyperkalemia

The management of hyperkalemia involves several critical steps:

1. Monitoring: Patients should be closely monitored for arrhythmias and electrolyte imbalances.

2. Medication Review: It is crucial to discontinue any medications that contain potassium or have potassium-sparing properties. This includes potassium-sparing diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain nutritional supplements.

3. Dietary Restrictions: Patients should avoid foods high in potassium, such as almonds, apricots, bananas, various beans, cantaloupe, carrot juice (canned), figs, grapefruit juice, halibut, milk, oat bran, potatoes (with skin), salmon, spinach, and tuna.

4. Calcium Administration: If the patient is at low or no risk of digitalis toxicity, intravenous calcium gluconate may be administered.

5. Insulin and Dextrose: An intravenous infusion of 300-500 mL/hr of a 10% dextrose solution containing 10-20 units of crystalline insulin per 1,000 mL is recommended.

6. Acidosis Correction: If acidosis is present, intravenous sodium bicarbonate should be administered to correct the condition.

7. Dialysis: In severe cases, hemodialysis or peritoneal dialysis may be necessary to effectively lower potassium levels.

8. Use of Exchange Resins: While exchange resins can be utilized, they should not be relied upon as the sole treatment for acute hyperkalemia.

It is important to note that lowering potassium levels too rapidly in patients who are taking digitalis can lead to digitalis toxicity. Additionally, in patients with impaired potassium excretion mechanisms, such as those with chronic renal failure or severe myocardial damage, the administration of potassium citrate can lead to hyperkalemia and potentially fatal cardiac arrest. Therefore, potassium citrate should be avoided in these populations.

In cases where severe gastrointestinal symptoms such as vomiting, abdominal pain, or gastrointestinal bleeding occur, potassium citrate should be discontinued immediately, and the possibility of bowel perforation or obstruction should be investigated.

Nonclinical Toxicology

Animal reproduction studies have not been conducted to evaluate the teratogenic potential of potassium citrate. Consequently, it remains unknown whether potassium citrate can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Therefore, potassium citrate should be administered to pregnant women only if clearly needed.

Regarding non-teratogenic effects, the normal potassium ion concentration in human milk is approximately 13 mEq/L. However, it is not established whether potassium citrate influences this concentration. As such, potassium citrate should be given to breastfeeding women only if clearly needed.

No specific details regarding nonclinical toxicology or animal pharmacology and toxicology are available in the insert.

Postmarketing Experience

No specific postmarketing experience details have been reported. As such, there are no additional adverse events or rare case reports to summarize at this time.

Patient Counseling

Patients should be advised to take each dose of the medication without crushing, chewing, or sucking the tablet to ensure proper absorption and effectiveness. It is crucial for patients to take this medicine only as directed, particularly if they are also using diuretics and digitalis preparations, as this can affect the medication's efficacy and safety.

Patients should be encouraged to communicate with their healthcare provider if they experience any difficulty swallowing the tablets or if they feel that the tablet is sticking in their throat. Additionally, patients must be instructed to seek immediate medical attention if they notice tarry stools or any other signs of gastrointestinal bleeding, as these may indicate serious side effects.

Healthcare providers should inform patients that regular blood tests and electrocardiograms will be performed by their doctor to monitor their health and ensure the safety of the treatment. This ongoing assessment is essential for managing any potential risks associated with the medication.

Storage and Handling

The product is supplied in a tight container to ensure stability and integrity. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). Proper adherence to these storage conditions is essential for maintaining the product's efficacy and safety.

Additional Clinical Information

No further data are available.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Potassium Citrate as submitted by Camber Pharmaceuticals, Inc. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)